BC PharmaCare Considering Daklinza. This is Not a Drill.

Daclatasvir (DAKLINZA) Survey LogoBC PharmaCare’s Daklinza (daclatasvir) Survey

Daklinza (generic name daclatasvir)* is being considered for BC PharmaCare coverage! Your input is wanted.

Input from patients, caregivers, and patient groups into Daklinza’s PharmaCare approval process is being gathered from Wednesday July 22, 2015 to MIDNIGHT on Wednesday August 19, 2015.

If you are a BC resident and answer YES to any of the following questions, you can add your input into whether or not Daklinza should be covered by BC PharmaCare:

Additional Information about Daklinza (daclatasvir)

For more information about Daklinza (daclatasvir) or the PharmaCare surveys, please contact PharmaCare’s Your Voice or the Hepatitis C Treatment Information Project.

Thank you for taking the time to voice your opinion and help advocate for a better tomorrow.

*Daklinza (daclatasvir) hasn’t received a Notice of Compliance from Health Canada yet and, therefore, still can not be bought in Canada. Also, according to Advanced Notices sent out by BC PharmaCare a couple of weeks ago, there were plans to collect patient input for Sunvepra (asunaprevir) as well. The Hepatitis C Treatment Information Project will keep you informed of any of its developments.